JP2010510223A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010510223A5 JP2010510223A5 JP2009537223A JP2009537223A JP2010510223A5 JP 2010510223 A5 JP2010510223 A5 JP 2010510223A5 JP 2009537223 A JP2009537223 A JP 2009537223A JP 2009537223 A JP2009537223 A JP 2009537223A JP 2010510223 A5 JP2010510223 A5 JP 2010510223A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- tim
- antigen
- activity
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 claims description 61
- 239000003795 chemical substances by application Substances 0.000 claims description 39
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 37
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 37
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 37
- 229920001184 polypeptide Polymers 0.000 claims description 27
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 27
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 27
- 102100031351 Galectin-9 Human genes 0.000 claims description 17
- 101710121810 Galectin-9 Proteins 0.000 claims description 17
- 239000000427 antigen Substances 0.000 claims description 17
- 102000036639 antigens Human genes 0.000 claims description 17
- 108091007433 antigens Proteins 0.000 claims description 17
- 230000000694 effects Effects 0.000 claims description 17
- 239000003446 ligand Substances 0.000 claims description 14
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 241001465754 Metazoa Species 0.000 claims description 8
- 102000002689 Toll-like receptor Human genes 0.000 claims description 7
- 108020000411 Toll-like receptor Proteins 0.000 claims description 7
- 230000028993 immune response Effects 0.000 claims description 7
- 210000003169 central nervous system Anatomy 0.000 claims description 3
- 201000007455 central nervous system cancer Diseases 0.000 claims description 3
- 208000025997 central nervous system neoplasm Diseases 0.000 claims description 3
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 claims description 2
- 239000000556 agonist Substances 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 description 15
- 229960005486 vaccine Drugs 0.000 description 15
- 125000003275 alpha amino acid group Chemical group 0.000 description 8
- 239000012634 fragment Substances 0.000 description 7
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 5
- 102100022338 Integrin alpha-M Human genes 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 4
- 210000004443 dendritic cell Anatomy 0.000 description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000000274 microglia Anatomy 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 206010018338 Glioma Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 201000004066 Ganglioglioma Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 201000004058 mixed glioma Diseases 0.000 description 1
- 206010073131 oligoastrocytoma Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85939106P | 2006-11-15 | 2006-11-15 | |
| US92394507P | 2007-04-17 | 2007-04-17 | |
| PCT/US2007/024067 WO2008060617A2 (en) | 2006-11-15 | 2007-11-15 | Therapeutic uses of tim-3 modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010510223A JP2010510223A (ja) | 2010-04-02 |
| JP2010510223A5 true JP2010510223A5 (enExample) | 2012-01-26 |
Family
ID=39402274
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009537223A Withdrawn JP2010510223A (ja) | 2006-11-15 | 2007-11-15 | Ｔｉｍ−３調節物質の治療的使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20100061992A1 (enExample) |
| EP (1) | EP2081961A2 (enExample) |
| JP (1) | JP2010510223A (enExample) |
| AU (1) | AU2007319806A1 (enExample) |
| CA (1) | CA2668693A1 (enExample) |
| WO (1) | WO2008060617A2 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5569946B2 (ja) * | 2009-01-26 | 2014-08-13 | 国立大学法人 岡山大学 | 免疫抑制剤および自己免疫疾患の予防および治療剤 |
| CN103800906B (zh) * | 2009-03-25 | 2017-09-22 | 德克萨斯大学系统董事会 | 用于刺激哺乳动物对病原体的先天免疫抵抗力的组合物 |
| PL2581113T3 (pl) | 2010-06-11 | 2018-11-30 | Kyowa Hakko Kirin Co., Ltd. | Przeciwciało anty-tim-3 |
| US8841418B2 (en) | 2011-07-01 | 2014-09-23 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to TIM3 |
| CA2916638C (en) * | 2012-07-31 | 2021-01-12 | The Brigham And Women's Hospital, Inc. | Modulation of the immune response |
| US20140120157A1 (en) * | 2012-09-19 | 2014-05-01 | Georgetown University | Targeted liposomes |
| CN104853776B (zh) | 2012-10-12 | 2021-04-09 | 布里格姆及妇女医院股份有限公司 | 免疫应答的增强 |
| MX380857B (es) * | 2012-10-29 | 2025-03-11 | Univ Arkansas | Nuevos coadyuvantes y sistemas de administración para mucosas. |
| WO2015048312A1 (en) | 2013-09-26 | 2015-04-02 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| KR102248804B1 (ko) | 2014-03-12 | 2021-05-11 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소 |
| US10618963B2 (en) | 2014-03-12 | 2020-04-14 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| US10519237B2 (en) | 2014-03-12 | 2019-12-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| EP3116909B1 (en) | 2014-03-14 | 2019-11-13 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
| IL293212B2 (en) | 2014-05-28 | 2023-12-01 | Memorial Sloan Kettering Cancer Center | Anti-GITR antibodies and methods of using them |
| AU2015314756A1 (en) | 2014-09-13 | 2017-03-16 | Novartis Ag | Combination therapies of alk inhibitors |
| WO2016171722A1 (en) * | 2015-04-24 | 2016-10-27 | The Brigham And Women's Hospital, Inc. | Interactions between ceacam and tim family members |
| WO2016179194A1 (en) * | 2015-05-04 | 2016-11-10 | Jounce Therapeutics, Inc. | Lilra3 and method of using the same |
| CN107921087A (zh) | 2015-07-16 | 2018-04-17 | 百欧肯治疗有限公司 | 治疗癌症的组合物及方法 |
| CA3007233A1 (en) | 2015-12-02 | 2017-06-08 | Agenus Inc. | Antibodies and methods of use thereof |
| US20190367552A1 (en) * | 2016-03-04 | 2019-12-05 | Galectin Sciences, Llc | Selenogalactoside compounds for the prevention and treatment of diseases associated with galectin and the use thereof |
| FR3051192B1 (fr) * | 2016-05-13 | 2020-12-25 | Univ De Lorraine | Methode de purification de proteines recombinantes par affinite basee sur l'activite lectinique du domaine crd d'une galectine |
| MY195089A (en) | 2016-05-27 | 2023-01-10 | Agenus Inc | Anti-Tim-3 Antibodies and Methods of use thereof |
| KR102899060B1 (ko) | 2016-07-14 | 2025-12-12 | 브리스톨-마이어스 스큅 컴퍼니 | Tim3에 대한 항체 및 그의 용도 |
| AU2018265571B2 (en) | 2017-05-12 | 2022-09-29 | Galectin Sciences, Llc | Compounds for the prevention and treatment of diseases and the use thereof |
| WO2019023247A1 (en) * | 2017-07-25 | 2019-01-31 | Immutics, Inc. | TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND |
| AU2020214796A1 (en) | 2019-01-30 | 2021-07-29 | Truebinding, Inc. | Anti-Gal3 antibodies and uses thereof |
| EP3725370A1 (en) | 2019-04-19 | 2020-10-21 | ImmunoBrain Checkpoint, Inc. | Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease |
| KR102572804B1 (ko) * | 2020-02-25 | 2023-08-31 | 국립암센터 | CD11b+ 세포에서 TIM-3의 발현 수준을 측정하는 암 진단 또는 예후 예측을 위한 정보제공 방법 |
| US12281166B2 (en) | 2020-05-26 | 2025-04-22 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking Galectin-3 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7470428B2 (en) * | 2002-01-30 | 2008-12-30 | The Brigham And Women's Hospital, Inc. | Compositions and methods related to TIM-3, a Th1-specific cell surface molecule |
| JP2008500013A (ja) * | 2003-10-03 | 2008-01-10 | ザ ブライハム アンド ウイメンズ ホスピタル，インコーポレイテッド | Ｔｉｍ−３ポリペプチド |
-
2007
- 2007-11-15 AU AU2007319806A patent/AU2007319806A1/en not_active Abandoned
- 2007-11-15 US US12/514,602 patent/US20100061992A1/en not_active Abandoned
- 2007-11-15 WO PCT/US2007/024067 patent/WO2008060617A2/en not_active Ceased
- 2007-11-15 CA CA002668693A patent/CA2668693A1/en not_active Abandoned
- 2007-11-15 EP EP07867488A patent/EP2081961A2/en not_active Withdrawn
- 2007-11-15 JP JP2009537223A patent/JP2010510223A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010510223A5 (enExample) | ||
| Monnet et al. | Efficacy and safety of NI-0101, an anti-toll-like receptor 4 monoclonal antibody, in patients with rheumatoid arthritis after inadequate response to methotrexate: a phase II study | |
| JP7215997B2 (ja) | 前立腺特異的膜抗原（ｐｓｍａ）を標的とする三重特異性タンパク質と使用方法 | |
| Samy et al. | Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases | |
| Avci et al. | Targeting IL-6 or IL-6 receptor in rheumatoid arthritis: what’s the difference? | |
| US10392444B2 (en) | Tumor antigen specific antibodies and TLR3 stimulation to enhance the performance of checkpoint interference therapy of cancer | |
| Xu et al. | Resident microglia activate before peripheral monocyte infiltration and p75NTR blockade reduces microglial activation and early brain injury after subarachnoid hemorrhage | |
| Eriksson et al. | Expression of interleukin 1α and β, and interleukin 1 receptor antagonist mRNA in the rat central nervous system after peripheral administration of lipopolysaccharides | |
| US20130142755A1 (en) | Methods for Improving Immune Function and Methods for Prevention or Treatment of Disease in a Mammalian Subject | |
| Cook et al. | Granulocyte macrophage colony-stimulating factor receptor α expression and its targeting in antigen-induced arthritis and inflammation | |
| Xiao et al. | The IL-2/Anti-IL-2 complex attenuates cardiac ischaemia-reperfusion injury through expansion of regulatory T cells | |
| JP2004501631A5 (enExample) | ||
| Weber et al. | Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF‐3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma | |
| AU2010248935B2 (en) | Methods and compositions for treating lupus | |
| US20030007972A1 (en) | Cytokine antagonists and other biologics for the treatment of bone metastases | |
| JP2006523682A5 (enExample) | ||
| JP2011507891A5 (enExample) | ||
| JP2002537362A (ja) | ビオチン化ケモカイン抗体複合体 | |
| US20220242963A1 (en) | B-cell activating cd73 antibodies | |
| JP2021511296A (ja) | 糖尿病、肝炎、および／または炎症性肝疾患を治療するための方法 | |
| WO2020190977A1 (en) | Treatment of cancers using sephb4-hsa fusion proteins | |
| CN106459181A (zh) | α‑烯醇化酶特异性抗体及其在免疫疾病治疗中的使用方法 | |
| Lampson | Beyond inflammation: site-directed immunotherapy | |
| KR20200068746A (ko) | Il8의 emt 경로 차단 및 암 줄기 세포 극복(il8 bloking emt pathway and overcoming cancer stem cells) | |
| Koschella et al. | CD40 ligation in vivo induces bystander proliferation of memory phenotype CD8 T cells |